Lyell Immunopharma (LYEL) Stock Highlights

0.93 | -14.68%

2024-10-26 04:20:09

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Statistics

Range Today

0.87 1.16

Volume Today 14.48M

Range 1 Year

1.06 3.26

Volume 1 Year 245.28M

Range 3 Year

1.06 15.49

Volume 3 Year 736.2M

Range 10 Year

1.06 19.84

Volume 10 Year 781.59M

Highlights

Market Capitalization 294.4M (small)

Floating Shares 165.29M

Current Price 0.93

Price To Earnings -1.56

Price To Revenue -3.58K

Price To Book 0.42

Earnings Per Share -0.71

Payout Ratio 0%

Performance

Latest -14.68%

1 Month -36.3%

3 Months -41.51%

6 Months -59.57%

1 Year -42.59%

3 Years -93.28%

5 Years -95.04%

10 Years -95.04%

Benchmarks

Market Capitalization

150 / 368

Gross Profits

50 / 278

Total Revenue

125 / 300

Total Rank

186 / 368

Free Cashflow

258 / 352

Performance 5 years

320 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.